uterine fibroids
-
Myovant hormonal therapy gets FDA nod, setting up competition with AbbVie
Myovant hormonal drug Myfembree has won FDA approval as a treatment for uterine fibroid bleeding. The regulatory decision clears the way for the pill to compete against a similar AbbVie drug, but with a dosing advantage.
-
Hospitals, Medical Devices, Health Tech
Insightec wants to usher in a new era of incisionless surgery
The Israeli company’s technology uses the power of focused ultrasound guided by MR imaging to target conditions like essential tremor, Parkinson’s disease and neuropathic pain.
-
Pediatric device innovators forum explores state of focused ultrasound
This free livestream event, hosted by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), features clinical, regulatory and reimbursement experts discussing the topic “Focused Ultrasound for Pediatric Indications.”
-
FDA approves expanded label for InSightec’s ultrasound uterine fibroid device
The ExAblate device’s label, an ultrasound technology designed to treat uterine fibroids, has been adapted in order for it to be available to women who want to keep their uterus intact while still having the option to get pregnant.
Promoted
Eight examples of humanism in action during COVID-19 and the global racial reckoning
The Gold Corporate Council and nonprofit Arnold P. Gold Foundation share examples of the vast work underway to support compassion and inclusion in healthcare
Promoted
A status report on healthcare’s adoption of digital documents
The Covid-19 pandemic has given a new sense of urgency for healthcare organizations to shift parts of their business that rely on paper-based documents to digital documents. That’s just one of the findings of a survey of healthcare organizations in a new report.
